Summit Therapeutics' ivonescimab BLA was accepted by the FDA for EGFR-mutant NSCLC. The PDUFA date is set for November. SMMT carries an Alpha Score of 40.
Summit Therapeutics received FDA acceptance of its biologics license application for ivonescimab combined with chemotherapy in EGFR-mutant non-small cell lung cancer. The agency set a Prescription Drug User Fee Act target date of November.
The news was highlighted by a Seeking Alpha analyst who upgraded the stock to Buy. Ivonescimab, a PD-1/VEGF bispecific antibody, is already approved in China for certain lung-cancer indications. The U.S. application covers the first-line setting in patients with EGFR mutations who have progressed on a tyrosine kinase inhibitor.
Summit shares have been volatile this year as investors weighed the drug's clinical trajectory against the commercial opportunity in a landscape that includes Tagrisso from AstraZeneca and the PD-1 class. The November PDUFA provides a clear catalyst for the stock.
Summit Therapeutics carries an AlphaScala Score of 40 out of 100, reflecting a mixed outlook in the healthcare sector. The full profile is available on the SMMT stock page.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.